Kolin 2

Researchers are evaluating AZD4144 in adults aged 18 to 80 years who have sepsis caused by a suspected or confirmed bacterial infection and have developed acute kidney injury within 72 hours of sepsis onset. This Phase IIa study is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy, safety, and tolerability of AZD4144 compared to placebo. The main goal is to compare kidney function measurements between participants receiving AZD4144 and those receiving placebo. Participants will be randomly assigned to receive either intravenous AZD4144 or a matching placebo once daily for a fixed treatment period according to the study protocol. The study includes a screening period, followed by the treatment period during which the study drug or placebo is administered daily. After treatment, participants will be monitored daily while hospitalized and will have up to two outpatient follow-up visits after discharge. During the study, participants will undergo daily safety monitoring, blood and urine sample collection, and various assessments to evaluate kidney function and other health outcomes. Researchers will measure specific kidney function markers such as creatinine clearance and serum cystatin C during treatment, and monitor participants for up to about 30 days for additional health outcomes including kidney replacement therapy use and survival. Safety and tolerability will also be assessed throughout the study period.

This study evaluates the long-term safety and tolerability of pelacarsen TQJ230 in people with established cardiovascular disease and elevated Lipoproteina who completed a previous related study. It is an open-label extension trial, meaning all participants receive the study drug without placebo comparison. The trial is sponsored by Novartis Pharmaceuticals and focuses on continued treatment after the completion of the parent study. Participants receive monthly injections of pelacarsen 80 mg subcutaneously for up to 36 months during this extension phase. This phase is designed to provide access to the study drug after the initial trial and to monitor participants closely. The study does not involve randomization or blinding, and all enrolled participants receive the active drug. During the study, participants will undergo regular assessments including monitoring for adverse events and cardiovascular events, as well as measuring Lipoproteina levels at baseline and several time points over 36 months. Safety and tolerability will be closely tracked throughout the treatment period. The total duration of participation corresponds to the length of the extension phase, up to three years.

Researchers are studying which of three eye drop medicationsbromfenac 0.09%, nepafenac 0.3%, and diclofenac 0.1%is more effective in preventing and treating cystoid macular oedema following cataract surgery. The study aims to find out which drug better prevents this condition and to compare the medical problems participants might have when using different drugs. Participants will be randomly assigned to use one of these drugs before and after their cataract surgery. Participants will use eye drops in their operated eye for up to 26 days, starting four days before surgery and continuing for 21 days after. The bromfenac group applies drops twice daily, the nepafenac group once daily, and the diclofenac group four times daily. This dosing schedule is followed throughout the treatment period to assess and compare the drugs effects. During the study, participants will visit the clinic for exams on the first day, one week, three weeks, and six weeks after surgery. Assessments include retina examination using optical coherence tomography OCT, vision tests, and questionnaires about their quality of life. Researchers will track the presence of macular oedema over six weeks and monitor changes in vision-related quality of life. The total participation lasts about six weeks after surgery with regular follow-up visits.

Overactive bladder OAB is a common health issue affecting 15-20% of adults, but less than half seek medical help. This research aims to raise awareness of OAB and improve referrals to specialists who can provide appropriate diagnosis and treatment. The project is led by the Institute of Health Information and Statistics of the Czech Republic and focuses on early detection and reducing the negative impact of OAB on quality of life. The study uses an online screening tool available via a web platform and mobile app, where participants complete validated questionnaires related to OAB symptoms, personal and family history, and quality of life. Those with positive screening results are offered an examination by specialists such as gynecologists, urogynaecologists, or urologists. Specialists access participant profiles through the platform, confirm or rule out OAB, perform additional diagnostic tests if needed, and set up standard treatments. Participation requires consent to data processing under GDPR. Participants will provide data through the online tool and may attend follow-up examinations with specialists. The study tracks outcomes including the number of participants completing the screening, those agreeing to specialist visits, confirmed diagnoses, and follow-up attendance over an average period of six to nine months. Data collected will evaluate the pilot projects effectiveness and cost, with all information stored securely respecting privacy regulations.

Researchers are evaluating tozorakimab as an additional treatment to standard care in adults hospitalized with viral lung infection who need supplemental oxygen. The study aims to determine if tozorakimab can help prevent death or the need for invasive mechanical ventilation or extracorporeal membrane oxygenation. This Phase III trial involves a large group of participants to assess the safety and effectiveness of this approach. Participants are randomly assigned to one of two groups one group receives a single intravenous dose of tozorakimab on the first day, while the other group receives a matching placebo. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given. This helps ensure unbiased results. The treatments are given once, and participants continue to receive standard care during the trial. During the study, participants are closely monitored and evaluated up to 60 days after treatment. Researchers track important outcomes such as death rates, progression to invasive ventilation, days alive outside intensive care, and oxygen use. They also assess clinical progression using a World Health Organization scale and monitor for any anti-drug antibodies. The trial lasts until November 2027, with multiple assessments throughout to understand the treatments impact and safety.

Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to standard care in hospitalized adults with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, double-blind study aims to compare trimodulin plus standard care against placebo plus standard care. The study also investigates detailed pharmacokinetic and pharmacodynamic properties of trimodulin. Participants will be randomly assigned to receive either trimodulin a human immunoglobulin solution containing IgM, IgA, and IgG or a placebo human albumin 1% via intravenous infusion once daily for five consecutive days alongside standard care. After treatment, participants will enter a follow-up phase lasting up to 23 days, including an end-of-follow-up visit or phone call on day 29. If still hospitalized after day 29, extended follow-up continues until discharge or day 90, followed by a closing visit or call around day 91. During the study, participants undergo various assessments including monitoring of mortality rates up to 28 and 90 days, changes in organ failure scores, clinical cure of pneumonia, ventilator and oxygen use, ICU and hospital stay durations, readmission rates, adverse events, lab tests, electrocardiograms, and vital signs. Safety evaluations and outcome measurements occur throughout treatment and follow-up, with total participation lasting up to approximately 90 days.